

0959-8049(95)00579-X

Correction

Postoperative adjuvant randomised trial comparing chemo-endocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from The Nishinihon Cooperative Study Group of Adjuvant Chemo-endocrine Therapy for Breast Cancer (ACETBC) of Japan—This paper by Morimoto *et al.* was published in the *European Journal of Cancer*, Vol. 32A, No. 2, pp. 235–242, 1996. The authors would like to apologise for

the following errors which occurred in the paper. Firstly, the administered dose of tamoxifen of 20 mg/day described in three regimens (A, B and C) and mentioned in the Abstract, the Patients and Methods section and in the legend to Figure 1 is incorrect and should have been 30 mg/day. Secondly, in Figure 3 the *P*-value in the 5-year overall survival curve should have been $P = 0.60$ and not $P = 0.060$ as originally stated.